Amdipharm`s Zonegran Receives Approval in Europe
French inspectors find issues at Indian plant cited earlier by Italy
EU Regulators Send Statements of Non-Compliance for Drugmakers in Spain, Italy, India
Mercury Laboratories Fails EDQM Inspection
The company decided to end the trial because of the difficulties in getting enough patients enrolled. It indicates that the company still felt confident in its potential as a commercial product.
Concordia International Corp.’s $4.9 billion debt-fueled acquisition spree is coming back to haunt the Canadian drugmaker’s lenders.
Concordia didn’t give a reason for the switch, noting only that Thompson and the board agreed that “this would be the ideal time for a leadership change.” But he’s not the only chief exec to exit his role in what’s been a tricky year for specialty drugmakers, Concordia included.
Pharmaceutical companies are emerging as the latest pocket of sorrow in the beleaguered junk-bond market as a renewed public debate on drug-pricing tactics unnerves investors.
A Canadian drugmaker with quite the track record for buyouts has struck a far-reaching deal that it says will enhance its M&A strategy. No, it's not serial dealmaker Valeant ($VRX)--but it may have Valeant worried.
Cancer Biotech TRACON Pharmaceuticals Files For a $58 Million IPO